CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercialising innovative therapeutics and pharmaceutical products, announced on Monday that it has named Daniel Lang, MD as its new chief financial officer and senior vice president.

Dr Lang has over 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF. He has 20 years of investment experience as a portfolio manager at Farallon Capital, and chief investment officer at RS Investments Value Group. He has most recently served as the president of Athenex cell therapy division and headed clinical development of the NKT cell platform.

Dr Wei-Wu He, CASI Pharmaceuticals chairman and CEO, said, 'We are delighted to have Dan join us at this exciting time at CASI. His unique combination of clinical, operational and capital market experience will contribute to the strategic pivot of anti-CD38 program to focus on antibody mediated rejection (AMR) and Idiopathic thrombocytopenia purpura (ITP).'